Peter S. Kim, Ph.D., was president of Merck Research Laboratories, 2003-2013. Kim joined the Company in 2001 as executive vice president, Research and Development. He was promoted to president in January 2003. In this role Kim oversaw all of Merck's drug and vaccine research and development activities. During his tenure, Merck gained approval of more than 20 new medicines and vaccines. These include Januvia, Gardasil, Isentress, Zostavax, Rotateq, and Victrelis. In 2013, he retired from Merck and was succeeded by Roger Perlmutter Kim grew up in Ridgewood, New Jersey, the son of a single mother, and his first job was in 1974 at a Roy Rogers restaurant, where he earned money to pay for college. Kim earned his A.B. in chemistry at Cornell University in 1979 and trained as a Ph.D. in Biochemistry at Stanford University under the guidance of Robert Baldwin. While at Stanford, he was also a Medical Scientist Training Program Fellow. Later, Kim was a Whitehead Fellow at the Whitehead Institute before joining Massachusetts Institute of Technology as a Professor of Biology and as a Member of the Whitehead Institute and an Investigator at the Howard Hughes Medical Institute.